N9741: A phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 2, Issue 2, 2002, Pages 81-

  Goldberg, Richard M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; BOLUS INJECTION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG INFUSION; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NOTE; PARESTHESIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

EID: 0036696879     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70509-6     Document Type: Note

References (3)

1. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-II + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-II in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 2002; 21:128a (Abstract #511).
2. Meta-analysis Group in Cancer: The efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
3. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (CRC): final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20:124a (Abstract #494).